Sign in
CompletedPhase 2

Effect of Endotoxin on Alcohol Consumption

Key facts

Who runs it
Yale University
Where
New Haven, United StatesSee the site
Trial code
Status
Completed
Phase
Phase 2
People taking part
27 people enrolled
Started
27 Feb 2022
Ended
31 Oct 2024
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Endotoxin
Record updated
3 November 2025

Who can take part

Age
21 years to 65 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 21 criteriaShow less

Who can take part

  • Age 21-65
  • Able to read and write English
  • Meets DSM-5 criteria for current (past 6 months) alcohol use disorder
  • Drinking criteria: Males - Drinks > 14 drinks per week and exceeds 4 drinks per day at least twice per week; Females -Drinks > 7 drinks per week and exceeds 3 drinks per day at least twice per week
  • Must meet drinking criteria during a consecutive 30-day period within the 90 days prior to baseline
  • Laboratory sessions will be scheduled such that subjects will not have major responsibilities on the following day which might limit drinking during the self-administration session (e.g., job interview, exam)
  • Negative urine pregnancy test for women

Who cannot take part

  • A positive test result at intake appointment on urine drug screens conducted for illicit drugs, excluding cannabis
  • Past 30 day use of psychoactive drugs including anxiolytics and antidepressants
  • Women who are pregnant or nursing, or fail to use one of the following methods of birth control unless she or partner is surgically sterile or she is postmenopausal (hormone contraceptives [oral, implant, injection, patch, or ring], contraceptive sponge, double barrier [diaphragm or condom plus spermicide], or IUD)
  • Participants with any significant current medical conditions (neurological, cardiovascular [including hypertension or hypotension: sitting BP >160/100 or <90/60mmHg at baseline screening], endocrine, thyroid, renal, liver), seizures, delirium or hallucinations, or other unstable medical conditions including HIV
  • Current DSM-5 substance use disorders, other than alcohol or nicotine
  • Suicidal, homicidal or evidence of current (past 6-month) severe mental illness such as schizophrenia, bipolar disorder or major depression, or anxiety disorders
  • Subjects with medical conditions contraindicating alcohol use (e.g., liver enzymes ≥3× normal)
  • Subjects likely to exhibit clinically significant alcohol withdrawal during the study. We will exclude subjects who a) have a history of perceptual distortions, seizures, delirium, or hallucinations upon withdrawal, or b) have a score of > 8 on the Clinical Institute Withdrawal Assessment scale at intake appointments
  • Subjects >38 on the Alcohol Use Disorders Identification Test (AUDIT)
  • Subjects with recent (past 2 weeks) acute illness or vaccination
  • Subjects with >Grade 2 laboratory abnormalities on screening
  • Subjects treatment-seeking or who are currently in treatment for alcohol use
  • Participation within the past 8 weeks in other studies that involve additive blood sampling and/or interventional measures that would be considered excessive in combination with the current application
  • Subjects with resting pulse >100 at challenge

Where in United States

  • Yale School of MedicineNew Haven, United States

About the trial

What the trial wants to find out

For this protocol, the investigators plan to collect pilot data to examine the effect of endotoxin on drinking behavior in the human laboratory.

The 2 groups in the trial

  • EndotoxinTreatment being tested

    Endotoxin (0.4ng/kg i.v.) will be administered one time during the laboratory session.

  • PlaceboPlacebo, for comparison

    Administered one time during the laboratory session.

    Treatment: Endotoxin

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Does Endotoxin Administration Increase Alcohol Consumption in Individuals With AUD?
Record updated
3 November 2025